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Background:  Adeno-associated virus (AAV) has become one of the most promising tools for gene therapy but more work required to 
improve its tissue/cell-specificity and reduce production cost.
methods:  This study aimed to evaluate the tropism of AAV9 vectors produced with rBac-based system. AAV9-CMV-eGFP and AAV9-CBA-
eGFP were produced using a recombinant baculovirus system and injected into mice via tail vein. The eGFP expression in different organs 
were analyzed by fluorescence imaging and western blot. The viral genomic quantities were measured by quantitative real-time PCR. 
Transduction efficiency of AAV9 vectors in primary cardiomyocytes and hepatocytes were determined by fluorescence microscope and flow 
cytometry in vitro, and TUNEL analysis was used for apoptosis.
results:  AAV9 viral particles packaged by rBac system were fully functional in vivo and in vitro, which drove eGFP transgene expression 
in mouse cardiac and liver tissues, but the expression in other tissues was limited at the dose of 1 × 1011 vector genomes per mouse 
at week 5. CMV promoter drove strong cardiac transgene expression and viral distribution, while CBA promoter resulted in robust eGFP 
expression and high vector DNA copy numbers in mouse liver. GFP expression in the heart and liver is time dependent. Meanwhile, both 
AAV promoters did not induce cell apoptosis in vitro.
Conclusion:  AAV9-CMV could efficiently direct cardiac gene transfer, whereas AAV9-CBA might be used as a tool for liver gene therapy. 
